Exelixis
EXEL
#2073
Rank
HK$59.63 B
Marketcap
HK$209.06
Share price
-2.83%
Change (1 day)
25.22%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): HK$2.22

According to Exelixis's latest financial reports the company's current EPS (TTM) is HK$2.21. In 2022 the company made an earnings per share (EPS) of HK$4.44 a decrease over its 2021 EPS that were of HK$5.77.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)HK$2.22-49.95%
2022HK$4.44-22.97%
2021HK$5.77100%
2020HK$2.88-65.09%
2019HK$8.26-53.91%
2018HK$17.93333.96%
2017HK$4.13-260.61%
2016-HK$2.57-58.75%
2015-HK$6.24-42.45%
2014-HK$10.845.3%
2013-HK$10.2943.48%
2012-HK$7.17-264.29%
2011HK$4.37-165.88%
2010-HK$6.63-32.54%
2009-HK$9.82-17.65%
2008-HK$11.9375.86%
2007-HK$6.78-25.64%
2006-HK$9.128.33%
2005-HK$8.42-42.86%
2004-HK$14.7330.34%
2003-HK$11.30-5.23%
2002-HK$11.93-0.65%
2001-HK$12.00-51.88%
2000-HK$24.94

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
HK$27.29 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
HK$24.79 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
HK$14.20 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$30.95 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$110.30 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$109.80 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$14.50 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$77.95-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$6.55-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA